AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3206202
Drug: Chlorhexidine gel
RxNorm normalized name: chlorhexidine Oral Gel
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorhexidine gel (1% digluconate) applied in a custom tray for the mandibular arch, 10 min daily for 14 days with oral hygiene measures (toothbrush, toothpaste, dental floss)
Trial: 3206202
Drug: Chlorhexidine gel
RxNorm normalized name: chlorhexidine Oral Gel
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorhexidine gel (1% digluconate) applied in a custom tray for the mandibular arch, 10 min daily for 14 days without oral hygiene measures
Trial: 15723742
Drug: Oral nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nutritional supplements (237 mL/d of 4 or 8 kJ/mL) for 4 weeks
Trial: 11110008
Drug: Citalopram (active
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (active drug)
Trial: 2005733
Drug: 84 g
RxNorm normalized name: ZINC OXIDE 9.84 g in 50 mL TOPICAL LOTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 84 g of oatmeal
Trial: 2005733
Drug: 56 g
RxNorm normalized name: PETROLATUM 30.8 g in 56 g TOPICAL OINTMENT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 56 g of oat bran
Trial: 2005733
Drug: 84 g
RxNorm normalized name: ZINC OXIDE 9.84 g in 50 mL TOPICAL LOTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 84 g of oat bran
Trial: 2005733
Drug: 56 g
RxNorm normalized name: PETROLATUM 30.8 g in 56 g TOPICAL OINTMENT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 56 g of oatmeal
Trial: 2005733
Drug: 28 g
RxNorm normalized name: SM Syringe 28 g, 0.5cc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 28 g of farina (beta-glucan control)
Trial: 6824299
Drug: Subcutaneous bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous bupivacaine injection around the wound
Trial: 28238190
Drug: Resveratrol 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol 500 mg/day
Trial: 28238190
Drug: Resveratrol 40
RxNorm normalized name: RESVERATROL 400 mg / NICOTINAMIDE MONONUCLEOTIDE 500 mg / WHITE PEPPER 50 mg ORAL LOZENGE [Ascuoli]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol 40 mg/day
Trial: 20534325
Drug: L-carnitine-supplemented (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine-supplemented (10 mg/[kg d])
Trial: 15863374
Drug: Quadrivalent HPV
RxNorm normalized name: HPV, quadrivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent HPV vaccine (20 microg type 6, 40 microg type 11, 40 microg type 16, and 20 microg type 18) administered at day 1, month 2, and month 6.
Trial: 15863374
Drug: Placebo preparations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo preparations (two types).
Trial: 12787419
Drug: Flow group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flow group (Qa <600 mL/min or clinical criteria)
Trial: 8717471
Drug: Casodex (bicalutamide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Casodex (bicalutamide, 50 mg once daily) plus LHRH analogue (Zoladex 3.6 mg every 28 days or leuprolide 7.5 mg every 28 days)
Trial: 8717471
Drug: Flutamide (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flutamide (250 mg three times daily) plus LHRH analogue (Zoladex 3.6 mg every 28 days or leuprolide 7.5 mg every 28 days)
Trial: 8717471
Drug: Casodex (bicalutamide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Casodex (bicalutamide, 50 mg once daily) plus LHRH analogue
Trial: 8717471
Drug: Flutamide (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flutamide (250 mg three times daily) plus LHRH analogue
Trial: 1648598
Drug: Cyclic-alternating treatment
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic-alternating treatment with ifosfamide/etoposide (IE), cyclophosphamide, doxorubicin, and vincristine (CAV)
Trial: 1648598
Drug: Response-oriented treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Response-oriented treatment with IE therapy up to maximal response and subsequently an immediate switch to CAV
Trial: 1648598
Drug: Limited-stage disease
RxNorm normalized name: SAGE
DrugBank: Sage (DB10982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Limited-stage disease (LD) patients with cyclic-alternating treatment
Trial: 1648598
Drug: Limited-stage disease
RxNorm normalized name: SAGE
DrugBank: Sage (DB10982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Limited-stage disease (LD) patients with response-oriented treatment
Trial: 1648598
Drug: Extensive-stage disease
RxNorm normalized name: SAGE
DrugBank: Sage (DB10982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extensive-stage disease (ED) patients with cyclic-alternating treatment
Trial: 1648598
Drug: Extensive-stage disease
RxNorm normalized name: SAGE
DrugBank: Sage (DB10982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extensive-stage disease (ED) patients with response-oriented treatment
Trial: 30129806
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Nigella sativa and Vitex agnus-castus with citalopram
Trial: 28155305
Drug: Training programme
RxNorm normalized name: PUMP,LUTREPULSE PROGRAMMABLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Training programme for Tanzanian caregiver students in relational communication therapy (RCT)
Trial: 17449836
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of medication and contingencies
Trial: 17449836
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of medication and reward
Trial: 17449836
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of medication and response cost
Trial: 15057257
Drug: Sildenafil 100
RxNorm normalized name: sildenafil 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 100 mg before intercourse
Trial: 16459225
Drug: TAG meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAG meal (10 g of TAG oil)
Trial: 10802151
Drug: Enalapril, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril, 10 mg/day
Trial: 10802151
Drug: Nifedipine, 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine, 30 mg/day
Trial: 1353368
Drug: bisoprolol 10
RxNorm normalized name: bisoprolol 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bisoprolol 10 mg daily
Trial: 1353368
Drug: diazepam 5
RxNorm normalized name: diazepam 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diazepam 5 mg twice daily
Trial: 6143631
Drug: ICI 118551
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI 118551 (beta 2 antagonist)
Trial: 24559858
Drug: Botox injection
RxNorm normalized name: Botox
DrugBank: DaxibotulinumtoxinA (DB17929)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botox injection at the bladder neck (100 IU)
Trial: 24559858
Drug: Standard conservative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard conservative treatment (both groups)
Trial: 20620037
Drug: Tiotropium 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium 5 microg via Respimat inhaler once daily for 48 weeks
Trial: 20620037
Drug: Placebo via
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo via Respimat inhaler once daily for 48 weeks
Trial: 17289892
Drug: Celecoxib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (400 mg, twice daily starting on day 2 of cycle 1)
Trial: 17289892
Drug: Irinotecan (escalated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan (escalated doses of 180, 200, 220, and 260 mg/m2 in FOLFIRI regimen)
Trial: 15855216
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E supplementation at 400 mg/day for 9 months
Trial: 11939671
Drug: Continuous combined
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous combined hormone replacement therapy (Kliogest)
Trial: 9571328
Drug: High-salt diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-salt diet (255 mEq of sodium daily)
Trial: 9571328
Drug: Low-salt diet
RxNorm normalized name: Low-energy diets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-salt diet (85 mEq of sodium daily)
Trial: 7542021
Drug: Primary chemotherapy
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary chemotherapy in addition to best supportive care
Trial: 25352095
Drug: Control (untreated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (untreated patches)
Trial: 18518863
Drug: Galantamine (long-term
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galantamine (long-term treatment > 6 months)
Trial: 18518863
Drug: Galantamine (short-term
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galantamine (short-term treatment ≤ 6 months)
Trial: 16269184
Drug: pegylated interferon
RxNorm normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pegylated interferon α-2b (1.5 μg/kg once weekly) plus ribavirin (800 mg daily) for 48 weeks for HCV genotypes 1/4 and 24 weeks for genotypes 2/3
Trial: 29306047
Drug: Cognitive-behavioral strategy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral strategy for discontinuing long-term serotonin reuptake inhibitors (SRIs)
Trial: 24642779
Drug: Dairy dessert
RxNorm normalized name: Beano Dairy Defense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dairy dessert containing maltitol and scFOS (35g dosage)
Trial: 16012278
Drug: Naltrexone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (50 mg/d) + Cognitive Behavioral Therapy (12 sessions)
Trial: 16012278
Drug: Naltrexone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (50 mg/d) + Motivational Enhancement Therapy (4 sessions)
Trial: 16012278
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + Cognitive Behavioral Therapy (12 sessions)
Trial: 16012278
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + Motivational Enhancement Therapy (4 sessions)
Trial: 14964345
Drug: Lacteol group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lacteol group (2 capsules of Lacteol Fort twice a day for 4 weeks)
Trial: 14964345
Drug: Lacidophilin group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lacidophilin group (5 chewable tablets of Lacidophilin three times a day for 4 weeks)
Trial: 8759812
Drug: zofenopril (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: zofenopril (7.5 to 30 mg twice daily)
Trial: 7065839
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of dextroamphetamine (intravenous)
Trial: 7065839
Drug: Double-blind pimozide
RxNorm normalized name: Pimozide
DrugBank: Pimozide (DB01100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Double-blind pimozide treatment
Trial: 31358046
Drug: Micro-fragmented adipose
RxNorm normalized name: human adipose preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micro-fragmented adipose tissue injection (Lipogems®)
Trial: 27176822
Drug: Tdap vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tdap vaccine during pregnancy
Trial: 12006327
Drug: Ibandronate 2.5
RxNorm normalized name: ibandronate 2.5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibandronate 2.5 mg daily
Trial: 15197541
Drug: Ibandronate 20
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibandronate 20 mg intermittently
Trial: 15197541
Drug: Ibandronate 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibandronate 1.0 mg IV every 3 months
Trial: 15197541
Drug: Ibandronate 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibandronate 0.5 mg IV every 3 months
Trial: 9841833
Drug: Ia-TT conjugate
RxNorm normalized name: magnesium aluminum silicate type Ia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ia-TT conjugate (dose range, 3.75-63 microg of CPS component)
Trial: 9841833
Drug: Ib-TT conjugate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ib-TT conjugate (dose range, 3.75-63 microg of CPS component)
Trial: 2508417
Drug: Triphasic oral
RxNorm normalized name: CeeNU, triphasic oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triphasic oral contraceptive containing ethinylestradiol and levonorgestrel
Trial: 8749599
Drug: Triphasic oral
RxNorm normalized name: CeeNU, triphasic oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triphasic oral contraceptive containing ethinylestradiol and desogestrel
Trial: 6124805
Drug: Early phototherapy
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early phototherapy started at serum bilirubin 250 mumol/l
Trial: 6124805
Drug: Late phototherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Late phototherapy started at serum bilirubin 320 mumol/l
Trial: 29736552
Drug: Anodal tDCS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anodal tDCS over the left inferior frontal gyrus (l-IFG)
Trial: 29736552
Drug: Anodal tDCS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anodal tDCS over the left posterior superior temporal gyrus (l-STG)
Trial: 20578849
Drug: Immediate orthodontic
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate orthodontic loading (11 implants)
Trial: 20578849
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (9 implants)
Trial: 3082677
Drug: Topical nitroglycerin
RxNorm normalized name: nitroglycerin Topical Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical nitroglycerin vasodilator cream
Trial: 29314645
Drug: Placebo→tofacitinib 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo→tofacitinib 5 mg twice daily
Trial: 29314645
Drug: Placebo→tofacitinib 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo→tofacitinib 10 mg twice daily
Trial: 16612399
Drug: Vasodilators and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vasodilators and diuretics
Trial: 23792149
Drug: Adalimumab (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab (80 mg loading dose followed by 40 mg every 2 weeks)
Trial: 20629134
Drug: Exercise program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise program (6-month minimally supervised); attended a monthly exercise class and exercised at home three times weekly
Trial: 16093518
Drug: Perceived treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perceived treatment severity and life threat
Trial: 8777336
Drug: Captopril (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (25 mg b.i.d. for 3 months)
Trial: 8777336
Drug: Captopril (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (50 mg b.i.d. for 6 months)
Trial: 29249596
Drug: Telephone counseling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone counseling by pharmacist bi-monthly for one year
Trial: 17490976
Drug: Iron and
RxNorm normalized name: beef,iron and wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron and riboflavin supplementation (30 mg Fe and 6 mg riboflavin) with vitamin A-fortified rice
Trial: 12925454
Drug: Pexelizumab 2.0‐mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pexelizumab 2.0‐mg/kg bolus
Trial: 12925454
Drug: Pexelizumab 2.0‐mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pexelizumab 2.0‐mg/kg bolus and 0.05‐mg/kg per h infusion for 20 hours
Trial: 9122580
Drug: Surgical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical therapy (uvulopalatopharyngoplasty (UPPP), nasal surgery, maxillofacial surgery)
Trial: 1513833
Drug: Foamed gel
RxNorm normalized name: Rectal Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foamed gel dressing
Trial: 6186852
Drug: Once-daily dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily dosing of acebutolol
Trial: 6186852
Drug: Twice-a-day dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-a-day dosing of acebutolol
Trial: 31724343
Drug: Formulation AH
RxNorm normalized name: phenylephrine hydrochloride Chewable Tablet [Ah-Chew D]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation AH
Trial: 31724343
Drug: Formulation AK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation AK
Trial: 31724343
Drug: Reference (single-entity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference (single-entity tablets)
Trial: 28776077
Drug: Novel formulation
RxNorm normalized name: Novel Influenza-H1N1-09, all formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel formulation of abiraterone acetate (100 mg in fasted state)
Trial: 28776077
Drug: Novel formulation
RxNorm normalized name: Novel Influenza-H1N1-09, all formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel formulation of abiraterone acetate (200 mg in fasted state)
Trial: 28776077
Drug: Novel formulation
RxNorm normalized name: Novel Influenza-H1N1-09, all formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel formulation of abiraterone acetate (200 mg in fed state)
Trial: 28776077
Drug: Novel formulation
RxNorm normalized name: Novel Influenza-H1N1-09, all formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel formulation of abiraterone acetate
Trial: 28776077
Drug: Zytiga (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zytiga (1000 mg)
Trial: 21703101
Drug: Intranasal carbon
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal carbon dioxide (CO(2))
Trial: 21703101
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (no CO(2))
Trial: 1291203
Drug: Formula-fed with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formula-fed with supplementary zinc 1.14-2.28 mg/kg/d
Trial: 6439639
Drug: Hyperosmolar basic
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperosmolar basic nutrition solution (3% amino acids, carbohydrates and electrolytes, 806 mosm/l)
Trial: 6439639
Drug: Isoosmolar electrolyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoosmolar electrolyte solution (299 mosm/l)
Trial: 29528793
Drug: Fruquintinib (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fruquintinib (5 mg once daily in 4-week cycles of 3 weeks on, 1 week off)
Trial: 25312546
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group receiving feedback regarding assessment results and recommendations for subsequent treatment.
Trial: 25312546
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving treatment as usual and global feedback regarding assessment results without recommendations.
Trial: 21243280
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no massage therapy)
Trial: 18456137
Drug: Immediately loaded
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediately loaded OMIs (up to 250 g of direct force applied immediately)
Trial: 17080220
Drug: Insulin treatment
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin treatment for glycaemic control
Trial: 10030506
Drug: Electronic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electronic treatment suggestions for heart failure, ischemic heart disease, reactive airways disease, and uncomplicated hypertension.
Trial: 10030506
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no access to electronic treatment suggestions).
Trial: 7554309
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone replacement (0.125 IU/kg/week for the first month and 0.25 IU/kg/week thereafter)
Trial: 2256971
Drug: One-injection-site peribulbar
RxNorm normalized name: Gel-One Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-injection-site peribulbar anesthesia
Trial: 29945252
Drug: L-AmB 10
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-AmB 10 mg/kg on day 1 (single dose)
Trial: 29945252
Drug: L-AmB 10
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-AmB 10 mg/kg on day 1 and 5 mg/kg on day 3 (2 doses)
Trial: 29945252
Drug: L-AmB 10
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-AmB 10 mg/kg on day 1 and 5 mg/kg on days 3 and 7 (3 doses)
Trial: 29945252
Drug: L-AmB 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-AmB 3 mg/kg/day for 14 days (control)